PANW · investment memo
base, with the FULL range run as a sensitivity. Evidenced trajectory: -3.4% (FY22) -> 5.6% -> 8.5% -> 13.5% GAAP operating margin. 20.0% is ABOVE the trailing actual, i.e. it credits continued expansion; the memo shows the criterion FAILS at EVERY terminal operating margin tested, so the terminal margin is not the parameter driving the result.
Four distinct questions, one field each. A price is not a thesis: the trigger below forces a re-underwrite and freezes further purchases — it is never an automatic sell.
A daily close below $264.98 triggers a mandatory re-underwrite and freezes further purchases. It is not an automatic sell unless a separate fundamental invalidation condition has been breached.
Not stated. This name has no falsifiable invalidation conditions on file, so it cannot be risk-monitored. That is a gap in the research, not a clean bill of health — recorded rather than hidden.
Type: MEASURED. Logged, scored, and it does not reject the name — the Valuation Criteria already does. Scenario — multiple compression toward its own history as the acquisition anniversaries and organic growth becomes visible in the reported line. Probability 45% — the highest in the cluster, and the only one above one-in-three. Named cause and mechanism, with a date. Reported growth is ~31% today and ~37% over the next twelve months purely because CyberArk and Chronosphere are consolidating into a base that excluded them. In Q3 FY2027 — the quarter ending April 2027 — the acquisitions fully a